BACKGROUND Nowadays, biomedical research has been focusing on the design and development of new drug delivery systems that provide efficient drug targeting. The molecularly imprinted polymers (MIPs) have attracted wide interest and play an indispensable role as a drug carrier. Drug delivery systems based on MIPs have been frequently cited in the literature. They are cross-linked polymers that contain binding sites according to the complementary structure of the template molecules. They possess distinctive features of structure predictability and site recognition specificity. Versatile applications of MIPs include purification, biosensing, bioseparation, artificial antibodies, and drug delivery. An ideal MIPs should include features such as biocompatibility, biodegradability, and stability. OBJECTIVE In this article, we elaborate on the historic growth, synthesis, and preparation of different MIPs and present an updated summary of recent advances in the development of new drug delivery systems which are based on this technique. Their potential to deliver drugs in a controlled and targeted manner will also be discussed. CONCLUSION MIPs possess unique advantages, such as lower toxicity, fewer side effects, and good therapeutic potential. They offer administration of drugs by different routes, i.e., oral, ocular or transdermal. Despite several advantages, biomedical companies are hesitant to invest in MIPs based drug delivery systems due to the limited availability of chemical compounds.

中文翻译：

---

药物输送系统中分子印迹聚合物的计算设计：综合回顾。

背景技术如今，生物医学研究一直集中于设计和开发提供有效药物靶向的新型药物递送系统。分子印迹聚合物（MIPs）引起了广泛的兴趣，并作为药物载体发挥着不可或缺的作用。基于 MIP 的药物输送系统经常在文献中被引用。它们是交联聚合物，根据模板分子的互补结构包含结合位点。它们具有结构可预测性和位点识别特异性的显着特征。MIP 的多种应用包括纯化、生物传感、生物分离、人工抗体和药物输送。理想的 MIP 应包括生物相容性、生物降解性和稳定性等特性。目的 在这篇文章中，我们详细阐述了不同 MIP 的历史发展、合成和制备，并提供了基于该技术的新药物输送系统开发的最新进展的更新总结。还将讨论它们以受控和有针对性的方式输送药物的潜力。结论 MIPs具有毒性低、副作用少、治疗潜力大等独特优势。它们提供通过不同途径给药，即口服、眼部或经皮。尽管有几个优势，但由于化合物的可用性有限，生物医药公司对投资基于 MIP 的药物输送系统犹豫不决。和准备不同的 MIPs，并提供基于该技术的新药物输送系统开发的最新进展的更新总结。还将讨论它们以受控和有针对性的方式输送药物的潜力。结论 MIPs具有毒性低、副作用少、治疗潜力大等独特优势。它们提供通过不同途径给药，即口服、眼部或经皮。尽管有几个优势，但由于化合物的可用性有限，生物医药公司对投资基于 MIP 的药物输送系统犹豫不决。和准备不同的 MIPs，并提供基于该技术的新药物输送系统开发的最新进展的更新总结。还将讨论它们以受控和有针对性的方式输送药物的潜力。结论 MIPs具有毒性低、副作用少、治疗潜力大等独特优势。它们提供通过不同途径给药，即口服、眼部或经皮。尽管有几个优势，但由于化合物的可用性有限，生物医药公司对投资基于 MIP 的药物输送系统犹豫不决。它们提供通过不同途径给药，即口服、眼部或经皮。尽管有几个优势，但由于化合物的可用性有限，生物医药公司对投资基于 MIP 的药物输送系统犹豫不决。它们提供通过不同途径给药，即口服、眼部或经皮。尽管有几个优势，但由于化合物的可用性有限，生物医药公司对投资基于 MIP 的药物输送系统犹豫不决。